Analyst Price Target is $23.30
▲ +18.45% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Fortrea in the last 3 months. The average price target is $23.30, with a high forecast of $27.00 and a low forecast of $20.00. The average price target represents a 18.45% upside from the last price of $19.67.
Current Consensus is
Reduce
The current consensus among 12 polled investment analysts is to reduce stock in Fortrea. This rating changed within the last month from a Hold consensus rating.
Fortrea
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Read More